Immunolocalization of Cytoplasmic ER in ER-negative Breast Carcinoma as a Potent Favorable Prognostic Predictor

It is known that estrogen receptor (ER) has extranuclear signaling functions in addition to classical genomic pathway, and estrogenic actions have been reported in ER-negative breast carcinoma cells. However, significance of cytoplasmic-ER immunoreactivity has not been reported in ER-negative breast...

Full description

Saved in:
Bibliographic Details
Published in:ACTA HISTOCHEMICA ET CYTOCHEMICA 2023/08/30, Vol.56(4), pp.59-66
Main Authors: Ebata, Akiko, Suzuki, Takashi, Shoji-Harada, Narumi, Hamanaka, Yohei, Miyashita, Minoru, Iwabuchi, Erina, Takagi, Kiyoshi, Miki, Yasuhiro, Tada, Hiroshi, Ishida, Takanori
Format: Article
Language:English
Subjects:
Breast cancer
Breast carcinoma
Chemotherapy
Epithelium
estrogen receptor
Estrogen receptors
immunohistochemistry
Immunoreactivity
Medical prognosis
prognosis
Regular
Xenoestrogens
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:It is known that estrogen receptor (ER) has extranuclear signaling functions in addition to classical genomic pathway, and estrogenic actions have been reported in ER-negative breast carcinoma cells. However, significance of cytoplasmic-ER immunoreactivity has not been reported in ER-negative breast carcinoma tissues. We immunolocalized cytoplasmic ER in 155 ER-negative breast carcinoma tissues and evaluated its clinicopathological significance including the prognosis. As a comparative cohort set, we also used 142 ER-positive breast carcinomas. Cytoplasmic-ER immunoreactivity was detected in the carcinoma cells, but not in the non-neoplastic mammary epithelium. Cytoplasmic-ER immunoreactivity was positive in the 35 out of 155 (23%) ER-negative breast carcinoma cases, whereas it was detected only in 2 out of 142 (1.4%) ER-positive cases. Cytoplasmic ER status was positively associated with cytoplasmic-PR status, but inversely associated with Ki67 labeling index or distant free-relapse survival rate. Moreover, cytoplasmic-ER status turned out to be an independent good prognostic factor for both distant relapse-free survival and breast cancer specific survival. These findings suggested that cytoplasmic ER plays important roles in the ER-negative breast carcinoma, and cytoplasmic ER is a potent good prognostic factor. Among the ER-negative breast cancer patients, clinical benefit of chemotherapy may be limited in the cytoplasmic-ER positive cases.
ISSN:0044-5991
1347-5800
DOI:10.1267/ahc.23-00016